SCHEMBL1149482

SCHEMBL1149482

COc1c(-c2cc(NC(=O)c3cccc(C(F)(F)F)c3)ccc2C)cc2cnc(N)nc2c1-c1ccc(F)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 9/20 0.61
KDR P35968 8/20 0.61
MAPK14 Q16539 7/20 0.61
JAK3 P52333 4/20 0.61
TEK Q02763 4/20 0.61
KIT P10721 4/20 0.51
CSF1R P07333 1/20 0.51
BTK Q06187 1/20 0.51
DDR2 Q16832 2/20 0.51
ABL1 P00519 2/20 0.51
BRAF P15056 6/20 0.49
RAF1 P04049 5/20 0.49
SYK P43405 1/20 0.48
PDGFRA P16234 2/20 0.46
EPHB4 P54760 2/20 0.46
FES P07332 1/20 0.46
RET P07949 1/20 0.46
PDGFRB P09619 1/20 0.46
FGFR1 P11362 1/20 0.46
SRC P12931 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1077470 0.94 LCK (0.61) LCKKDRMAPK14JAK3TEK
SCHEMBL1149113 0.94 KDR (0.62) LCKKDRMAPK14JAK3TEK
SCHEMBL1149752 0.93 LCK (0.64) LCKKDRMAPK14JAK3TEK
SCHEMBL1079169 0.93 LCK (0.63) LCKKDRMAPK14JAK3TEK
SCHEMBL1149100 0.91 LCK (0.63) LCKKDRMAPK14JAK3TEK
SCHEMBL1149421 0.91 LCK (0.64) LCKKDRMAPK14JAK3TEK
SCHEMBL1149463 0.90 LCK (0.59) LCKKDRMAPK14JAK3TEK
SCHEMBL1078560 0.90 LCK (0.61) LCKKDRMAPK14JAK3TEK
SCHEMBL1149396 0.90 LCK (0.61) LCKKDRMAPK14JAK3TEK
SCHEMBL1149456 0.88 LCK (0.62) LCKKDRMAPK14JAK3TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 LCK 3187/4885KDR 896/4885MAPK14 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.